- Home
- SOLV vs ROIV Comparison
SOLV vs ROIV Comparison
Compare SOLV & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- ROIV
- Stock Information
- Founded
- SOLV 2023
- ROIV 2014
- Country
- SOLV United States
- ROIV United Kingdom
- Employees
- SOLV N/A
- ROIV N/A
- Industry
- SOLV
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- ROIV Health Care
- Exchange
- SOLV NYSE
- ROIV Nasdaq
- Market Cap
- SOLV 11.1B
- ROIV 8.4B
- IPO Year
- SOLV N/A
- ROIV N/A
- Fundamental
- Price
- SOLV $66.18
- ROIV $12.30
- Analyst Decision
- SOLV Hold
- ROIV Strong Buy
- Analyst Count
- SOLV 5
- ROIV 10
- Target Price
- SOLV $58.25
- ROIV $17.33
- AVG Volume (30 Days)
- SOLV 1.1M
- ROIV 4.2M
- Earning Date
- SOLV 08-08-2024
- ROIV 08-08-2024
- Dividend Yield
- SOLV N/A
- ROIV N/A
- EPS Growth
- SOLV N/A
- ROIV N/A
- EPS
- SOLV 6.12
- ROIV 5.65
- Revenue
- SOLV $8,207,000,000.00
- ROIV $158,303,000.00
- Revenue This Year
- SOLV $2.00
- ROIV $45.51
- Revenue Next Year
- SOLV $0.05
- ROIV $42.29
- P/E Ratio
- SOLV $10.82
- ROIV $2.18
- Revenue Growth
- SOLV 1.31
- ROIV 101.44
- 52 Week Low
- SOLV $47.16
- ROIV $8.25
- 52 Week High
- SOLV $72.40
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- ROIV 65.79
- Support Level
- SOLV N/A
- ROIV $11.50
- Resistance Level
- SOLV N/A
- ROIV $12.60
- Average True Range (ATR)
- SOLV 0.00
- ROIV 0.35
- MACD
- SOLV 0.00
- ROIV 0.04
- Stochastic Oscillator
- SOLV 0.00
- ROIV 79.19
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.